Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Abstract

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

• Authors: Jackie K Imai, Gaurav Singh, Karl V Clemons, David A Stevens
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 48 Issue 10 Pg. 4063-6 (Oct 2004) ISSN: 0066-4804 [Print] United States
• PMID: 15388482 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Triazoles
• posaconazole
• Amphotericin B

Topics

• Amphotericin B (therapeutic use)
• Animals
• Antifungal Agents (therapeutic use)
• Aspergillosis (drug therapy)
• Aspergillus fumigatus
• Central Nervous System Fungal Infections (drug therapy, microbiology)
• Male
• Mice
• Survival
• Survival Analysis
• Triazoles (therapeutic use)